News & Events

06 April 2021 New clinical milestones reached as multiple COVID-19 vaccines and therapies advance

Plans for a late-stage test of Valneva SE's COVID-19 vaccine candidate, clinical progress on a different vaccine from Novavax Inc. and advancement for two midstage therapies targeting the virus made clear April 6 that industry efforts to battle the pandemic remain in high gear.

Read More

01 April 2021 38% of Detroit residents ‘very likely’ to get COVID-19 vaccine, University of Michigan survey finds

More Detroit residents are “very likely” to get the COVID-19 vaccine compared to last fall, a University of Michigan survey found.

Read More

31 March 2021 U-M Receives $1.4M in NIH Funding to expand COVID-19 outreach

Being deeply rooted in the wellbeing of Michigan communities meant that the Community Engagement program at the Michigan Institute for Clinical & Health Research, Michigan Medicine, and the U-M School of Public Health were on the frontlines when the pandemic hit the nation.

Read More

31 March 2021 One year of rapid acceleration of diagnostics, and anticipating new challenges

Over the past year, our team of NIH leaders has used this blog to report on an initiative called Rapid Acceleration of Diagnostics – or RADxSM for short.

Read More

24 March 2021 Long-Acting Antibody Therapy, AZD7442, for COVID-19 Begins Clinical Trial

AZD7442, an investigational long-acting antibody combination, is being evaluated in an international randomized, controlled Phase 3 clinical trial as part of the National Institutes of Health Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol.

Read More

22 March 2021 Vaccine recipients encourage Black community to vaccinate

Across the nation, COVID-19 has taken the lives of African Americans at a disproportionate rate, compared to white Americans.

Read More

21 March 2021 Convalescent plasma hype has faded but some say the Covid therapy still holds promise

The most promising use of the blood plasma treatment might come from “super donors,” people who were infected with Covid-19 and then vaccinated.

Read More

18 March 2021 Conquering COVID-19 Disparities Among Communities of Color

A federal NIH grant supports work to promote COVID-19 research and inclusivity among African Americans and Hispanics/Latino populations.

Read More

12 March 2021 Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report

Background Thrombosis may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.

Read More

11 March 2021 Listening is key to addressing senior living staff vaccine hesitancy: NIH senior adviser

Combatting vaccine hesitancy in senior living staff members is as easy as listening, according to a senior adviser in the National Institutes of Health.

Read More

10 March 2021 Convalescent Plasma Strikes Out As COVID-19 Treatment

More than half a million Americans have received an experimental treatment for COVID-19 called convalescent plasma. But a year into the pandemic, it's not clear who, if anyone, benefits from it.

Read More

09 March 2021 NIH launches last trial of anticoagulant treatments for Covid-19

The US National Institutes of Health (NIH) has initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with Covid-19.

Read More

07 March 2021 Local Leaders Build COVID Vaccine Trust in Black and Latinx Communities

When Rev. Mark-Anthony Middleton looks into the eyes of some of his elderly Black parishioners, he sees a deep, historic hurt that leads them to question the coronavirus vaccine.

Read More

04 March 2021 NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198. The sub-studies were halted by the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, on March 1, 2021, following an interim review and recommendation from the independent Data and Safety Monitoring Board (DSMB).

Read More

03 March 2021 Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial.

Read More

02 March 2021 NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms

The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in treating emergency department patients who developed mild to moderate symptoms of COVID-19, the disease caused by the coronavirus SARS-CoV-2.

Read More

24 February 2021 UCHealth Researchers Studying If Convalescent Plasma Can Keep High-Risk COVID Patients Out Of The Hospital

Researchers at UCHealth University of Colorado Hospital are looking at the effectiveness of convalescent plasma in keeping high-risk COVID-19 patients out of the hospital. They are trying to see if giving a patient, who shows up in the emergency department, the antibody-rich plasma will keep that person from being admitted.

Read More

17 February 2021 Virtual town hall Friday on vaccine hesitancy among marginalized communities

Black Alabamians and other marginalized groups are being vaccinated for COVID-19 in much fewer numbers than white Alabamians, and to help address vaccine hesitancy in minority communities, leaders from Tuskegee University and the University of Alabama at Birmingham School of Medicine will hold a virtual town hall on Friday.

Read More

16 February 2021 ASU part of state consortium that aims to reduce misinformation about COVID-19 in communities of color

Researchers at Arizona State University's Southwest Interdisciplinary Research Center, along with colleagues at Arizona’s two other state universities and Mayo Clinic, are working to reduce misinformation and mistrust about the COVID-19 pandemic among people disproportionately affected by it.

Read More

12 February 2021 Community Health Workers, Often Overlooked, Bring Trust to the Pandemic Fight

Public health authorities are relying on community health workers to be a bridge to communities that have been hardest hit by COVID-19.

Read More

10 February 2021 NAACP information sessions to provide health info to underserved communities

The Alabama Branch of the NAACP is hosting a series of free, online information sessions regarding COVID-19 vaccinations.

Read More

10 February 2021 International Phase III Trial of Long-Acting Antibodies for COVID-19 Launched

A National Institutes of Health Phase III trial of a long-acting antibody combination therapy developed by AstraZeneca for treating severe COVID-19 is now recruiting patients.

Read More

08 February 2021 Clinical trial in hospitalized COVID-19 patients evaluates long-acting antibody therapy

An international randomized, controlled Phase 3 clinical trial has begun evaluating the safety and efficacy of an investigational long-acting antibody combination for treating people hospitalized with COVID-19.

Read More

05 February 2021 NIH’s ACTIV-3 Covid-19 trial plans to add another mAb in few weeks; futility analysis GSK/Vir’s and Brii’s mAbs expected in February, sources say

The National Institutes of Health’s (NIH’s) Phase III ACTIV-3 trial will add another monoclonal antibody (mAb) therapy to its Covid-19 treatment platform in the next few weeks, said a source familiar with the study and a trial investigator.

Read More

04 February 2021 Alabama’s NAACP hosting information sessions to answer questions related to the COVID-19 vaccine

The Alabama NAACP will host a series of four info sessions to address questions and concerns related to the COVID-19 vaccine, according to a release from the organization.

Read More

02 February 2021 Can Blood Thinners Keep Certain COVID-19 Patients Out of the ICU?

COVID-19 patients receiving a full intravenous dose of heparin were less likely to need organ support

Read More

29 January 2021 UH Moment: Addressing Concerns About COVID-19 Vaccines

With many Americans skeptical about the safety and effectiveness of new vaccines, the University of Houston is working to understand why people are hesitant to be vaccinated and how to change their perceptions.

Read More

29 January 2021 Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients: Interim Analysis Results

Results of the interim analysis for a large clinical trial conducted worldwide with full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19.

Read More

28 January 2021 Pandemic spurs quest to enroll more Black Americans in vaccine trials

Infectious disease doctor Angela Branche needed help.

Read More

27 January 2021 Florida doctors push to make COVID-19 vaccine education accessible in minority communities

Minorities have been disproportionately affected by COVID-19, with more infections and deaths than any other group.

Read More

25 January 2021 NIH reports full-dose blood thinners improve Covid-19 outcome

The National Institutes of Health (NIH) has reported data from a large clinical trial, which showed that full-dose anticoagulation (blood thinners) lowered the need for vital organ support in moderately-ill, hospitalised Covid-19 patients.

Read More

22 January 2021 Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support—such as the need for ventilation.

Read More

22 January 2021 Pitt-Led NIH Trial Platform Shows Blood Thinners Decrease Need for Life Support in COVID-19 Patients

A worldwide set of clinical trials coordinated in part by researchers at the University of Pittsburgh has found that giving full dose anti-coagulation treatments, or blood thinners, to moderately ill patients hospitalized for COVID-19 reduced the need for vital organ support, such as ventilation. The researchers say that adopting the cheap, readily available treatment could help reduce the burden on intensive care units.

Read More

20 January 2021 UH researchers address COVID-19 vaccine hesitancy in minority communities

Many Americans, particularly minorities, are hesitant or skeptical about receiving the COVID-19 vaccine, and institutions, like the University of Houston, are hoping to change that.

Read More

16 January 2021 Tallahassee Memorial HealthCare participating in blood thinner study as COVID treatment

A research team at Tallahassee Memorial HealthCare has joined a national study to see if blood thinners can help prevent life-threatening blood clots from forming in the bloodstreams of people who have tested positive for COVID-19 and who do not require hospitalization.

Read More

15 January 2021 Lakeland Regional Health leads the state in COVID-19 blood clot research

LAKELAND, Fla. — Lakeland Regional Health is doing ground-breaking research that is answering crucial questions to help prevent complications from COVID-19.

Read More

14 January 2021 Tennessee vaccine shortage as doctors warn of new, aggressive virus strain

The Morehouse College School of Medicine has just released a new public service announcement urging people, particularly people of color, to get the COVID-19 vaccine “for you, for me, for all of us.”

Read More

13 January 2021 New Morehouse PSA urges vaccinations ‘for all of us’

Read More

11 January 2021 Tallahassee Memorial HealthCare researchers looking at blood thinners as possible COVID-19 treatment

TALLAHASSEE, Fla. (WCTV) - Tallahassee Memorial HealthCare says one of its research teams has joined a national study to evaluate blood thinners as a possible treatment for COVID-19 in patients who do not need to be hospitalized.

Read More

06 January 2021 NIH initiates trial of antibody combination therapy in Covid-19 patients

The National Institutes of Health (NIH) in the US has announced the initiation of a Phase II/III clinical trial of a combination investigational monoclonal antibody therapy for treating individuals with mild-to-moderate Covid-19.

Read More

05 January 2021 (BPRW) National Institutes of Health: The Power of Trust and Truth

Getting and sharing the facts about COVID-19, trusting science can help turn the tide for pandemic-strapped communities of color

Read More

28 December 2020 COVID Clot Prevention Evidence Beginning to Bud

Clotting problems with severe COVID-19 became clear in the early days of the pandemic; now at around the 1-year mark of the first cases, research is just beginning to reveal what prophylactic strategies are best.

Read More

24 December 2020 Statement from the REMAP-CAP trial: International Trials of Blood Thinners Pause Enrollment of Critically Ill COVID-19 Patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrolment for one group of patients.

Read More

23 December 2020 Mistrust of government is significant roadblock to Black American vaccination efforts

The rollout of the first approved COVID-19 vaccine this week is raising questions of when the game-changing inoculations will be ready for everyday Americans.

Read More

23 December 2020 NIH Sponsored ACTIV-3 Trial Results Published

Recent data from a Phase 3, randomized, placebo-controlled clinical trial that tested the investigative monoclonal antibody LY-CoV555 in hospitalized patients with the coronavirus disease 2019 (COVID-19), showed preliminary results that it did not provide any clinical benefit in comparison to a placebo.

Read More

23 December 2020 Lilly’s monoclonal antibody fails in NIH-sponsored ACTIV-3 trial

The US National Institutes of Health (NIH) has announced that preliminary results from a Phase III clinical trial of Eli Lilly and Company’s investigational monoclonal antibody, LY-CoV555, showed it failed to provide clinical benefit in hospitalised Covid-19 patients.

Read More

23 December 2020 Results of NIH-sponsored ACTIV-3 trial published

Preliminary results of Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published in The New England Journal of Medicine.

Read More

22 December 2020 NIH ACTIV Trial of blood thinners pauses enrollment of critically ill COVID-19 patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not reduce the need for organ support. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.

Read More

22 December 2020 Results of NIH-sponsored ACTIV-3 trial published

Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in The New England Journal of Medicine.

Read More

22 December 2020 A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.

Read More

21 December 2020 Some Black MS residents are skeptical of COVID vaccine. Can researchers change minds?

A few days ago, Vanessa Reed got a letter in the mail. A company called ClinicalResearch.com wanted her to know she could get up to $740 and potentially a free COVID-19 vaccine if she signed up for a clinical trial.

Read More

20 December 2020 Mistrust, disinformation among Latinos on Covid vaccine worries Hispanic doctors

MIAMI — As vaccinations against the coronavirus begin to roll out across the country, Dr. Olveen Carrasquillo says he's been getting many questions from his predominantly Latino patients, including whether the vaccine contains the virus and whether there are side effects to taking it.

Read More

17 December 2020 Investigational COVID-19 therapeutics to be evaluated in large clinical trials

Two randomized, controlled Phase 3 clinical trials have begun evaluating investigational monoclonal antibodies for their safety and efficacy in treating people hospitalized with moderate COVID-19.

Read More

10 December 2020 New nationwide collaborative study to determine factors that predict disease severity and long-term health impacts of COVID-19

A new nationwide study of more than 50,000 individuals is underway to determine factors that predict disease severity and long-term health impacts of COVID-19.

Read More

07 December 2020 Tulane receives $1 million NIH grant to engage communities hardest hit by COVID-19

The National Institutes of Health has awarded a $1 million grant to Tulane University to launch an outreach initiative to reach ethnic and racial minority communities in Louisiana that are disproportionately affected by the COVID-19 pandemic.

Read More

03 December 2020 Intermountain Healthcare Researchers launch New Study to determine whether Blood Thinners prevent clots, Illness severity in patients with COVID-19

Salt Lake City, Utah – As part of a national movement to develop treatments and therapies for COVID-19, Intermountain Healthcare researchers are launching a study in Utah to examine the effects of anticoagulants on patients who have tested positive for the novel coronavirus.

Read More

28 November 2020 The power of trust and truth sharing facts about COVID-19 Science can turn tide for communities of color

COVID-19 has killed more than 230,000 people in the U.S., and the death toll continues to rise at a rate of about 1,000 per day. We know, however, that families and communities don’t count their losses in thousands or hundreds; they count them one-by-one – a father, a teacher, a sister, a friend, a nurse, a son, a Tribal elder, a church member. And these losses hurt.

Read More

28 November 2020 WSU partners with Johns Hopkins to conduct COVID-19 plasma trials

Researchers at Wayne State University are studying the potential benefits of using convalescent blood plasma from COVID-19-infected donors on exposed and diagnosed patients, to see if antibodies can help fight SARS-CoV-2, the novel coronavirus which causes COVID-19.

Read More

19 November 2020 Knocking down the COVID-19 disparities through university community partnerships

The University of Arizona, in partnership with Arizona State University, Northern Arizona University and the Mayo Clinic in Scottsdale, made Arizona one of the 11 states that are participating in the National Institute of Health’s Community Engagement Alliance Against COVID-19 Disparities.

Read More

18 November 2020 Florida Universities and Health Centers Partner on COVID-19 Community Engagement, Research

Armed with a $1 million award from the National Institutes of Health (NIH), Universities and health care entities throughout the state of Florida are collaborating to provide outreach and engagement to ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic.

Read More

16 November 2020 Study of COVID-19 Risk and Long-Term Effects Underway at 37 U.S. Academic Medical Centers

A new nationwide study of more than 50,000 individuals is now underway to determine factors that predict disease severity and long-term health impacts of COVID-19.

Read More

16 November 2020 Bond Community Health Center enrolls Florida patients in national COVID-19 study

Bond Community Health Center in Tallahassee is the first site in Florida to enroll patients in a national study to see if blood thinners can help prevent life-threatening blood clots from forming in people who have tested positive for COVID-19.

Read More

12 November 2020 Amid Pandemic, American Lung Associate Expands Awards and Grants Research Investment on COVID-19, Lung Diseases

CHICAGO, Nov. 12, 2020 /PRNewswire/ -- The American Lung Association has expanded its awards and grants program through its COVID-19 Action Initiative to include 12 new COVID-19 research awards, and today announced an investment of approximately $11.55 million in promising research to fund an expected 98 awards for 2021.

Read More

10 November 2020 Lilly’s monoclonal antibody is the first to be authorized for use in treating COVID-19

Lilly's monoclonal antibody therapy, bamlanivimab (LY-CoV555), has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of adults and children with recently diagnosed, mild to moderate COVID-19.

Read More

03 November 2020 Physician-Scientist Leads Program to Tackle COVID-19 Health Disparities in Arizona

Dr. Sairam Parthasarathy is one of 11 principal investigators for the National Institutes of Health Community Engagement Alliance Against COVID-19 Disparities.

Read More

30 October 2020 AZ Orgs Prepare to Target Health Disparities, Community Health

University of Arizona Health Sciences will spearhead efforts to bolster community health outreach and engagement in light of COVID-19 disparities.

Read More

22 October 2020 Arterial wall cells offer insight into coronavirus’ rampage from head to toe

Peter Libby, M.D., never imagined nearly 40 years ago that his research would contribute to the current understanding of how the novel coronavirus targets and ravages the blood vessels in people with COVID-19.

Read More

20 October 2020 Morehouse School of Medicine awarded $1 Million NIH grant for COVID-19 community engagement research, health communications

Morehouse School of Medicine received a $1 million award from the National Institutes of Health for COVID-19 pandemic outreach and engagement efforts in ethnic and racial minority communities. Morehouse will form a statewide coalition as one of 12 support teams across the US that are established as part of the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

Read More

19 October 2020 NIH funds community engagement research efforts in areas hardest hit by COVID-19

The National Institutes of Health (NIH) recently announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities that are being disproportionately affected by the COVID-19 pandemic.

Read More

16 October 2020 Promising COVID-19 Research Awards Announced by American Lung Association, Clinical Trials Expanded with COVID-19 Research

As the COVID-19 pandemic reached the United States, the American Lung Association announced the COVID-19 Action Initiative, designed to accelerate the search for COVID-19 solutions.

Read More

16 October 2020 MSM Awarded $1 Million NIH Grant for COVID-19 Community Engagement Research and Health Communications

Morehouse School of Medicine received a $1 million award from the National Institutes of Health for COVID-19 pandemic outreach and engagement efforts in ethnic and racial minority communities.

Read More

16 October 2020 NIH Funds Community Engagement Research Efforts in Areas Hit Hardest by COVID-19

The National Institutes of Health today announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic.

Read More

15 October 2020 Equipoise, Trust, and the Need for Cardiologists to Randomize Patients Into Anticoagulation Trials in the Time of COVID

In collaboration with the National Heart Lung and Blood Institute, Operation Warp Speed, the United States Food and Drug Administration, and as part of the Accelerating COVID19 Therapeutic Interventions and Vaccines(ACTIV) initiative...

Read More

12 October 2020 UMMC begins NIH study on COVID-19, community engagement

The University of Mississippi Medical Center received a $1 million grant for community outreach and engagement in minority communities heavily affected by COVID-19.

Read More

12 October 2020 CHER receives $1.2 million for health equity COVID-19 research

Researchers in Northern Arizona University’s Center for Health Equity Research (CHER) and the Southwest Health Equity Research Collaborative (SHERC) recently received four grants totaling more than $1 million from the National Institutes of Health (NIH) for projects related to the COVID-19 pandemic.

Read More

09 October 2020 Meharry Investigator to Lead NIH Community Research in TN for Vulnerable COVID-19 Populations

Nashville, Tenn.—Meharry Medical College Investigator Dr. Paul Juarez will lead the Community Engagement Alliance Against COVID-19 Disparities (CEAL) Team in Tennessee through a new research initiative funded by the National Institutes of Health (NIH).

Read More

08 October 2020 COVID-19 Should Force “Soul-Searching” Over Fragmented US Clinical Trials System, Woodcock Says

Among hundreds of trials underway on potential therapeutics, only about 6% of study arms are expected to yield actionable data because most are nonrandomized, underpowered or underenrolled, Operation Warp Speed’s Janet Woodcock says, renewing her pitch for adoption of master protocols and other approaches to streamline studies and improve efficiency.

Read More

07 October 2020 Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

Read More

05 October 2020 Cary man shares his battle with COVID-19

I was at the point where I didn't think I was going to make it. I was really bad, suffering with the breathing and everything...

Read More

27 September 2020 Medicine faculty part of ACTIV-3 trial team lauded by NIH

A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.

Read More

25 September 2020 Duke Tests Novel COVID-19 Therapy, Is Lead Enroller in International Trial

The early stage of COVID-19 offers a critical window of opportunity to prevent the progression of the disease to the acute state, when patients require supportive care. By targeting the SARS-CoV-2 virus early on, a therapeutic can help to quickly eliminate the virus from the body while the patient’s symptoms are mild.

Read More

23 September 2020 COVID-19: An Update on the Federal Response

Chairman Alexander, Ranking Member Murray and distinguished members of Committee. It is an honor to appear before you today to discuss the Department of Health and Human Services’ ongoing response to the COVID-19 pandemic.

Read More

17 September 2020 HCS to lead state effort to raise awareness about COVID-19 in underserved communities

The University of North Texas Health Science Center at Fort Worth (HSC) will administer the Texas portion of a $12 million National Institutes of Health award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by COVID-19.

Read More

16 September 2020 NIH funds community engagement research efforts in areas hardest hit by COVID-19

Outreach will focus on COVID-19 awareness and education research, especially among African Americans, Hispanics/Latinos, and American Indians.

Read More

15 September 2020 NIH Launches antithrombotics trials in COVID-19 patients

The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.

Read More

15 September 2020 Bridging the Gap at Warp Speed – Delivering Options for Preventing and Treating Covid-19

Operation Warp Speed (OWS), an effort of the U.S. Department of Health and Human Services and the Department of Defense in partnership with the private sector, is providing financial investment, scientific support, regulatory expertise, and logistic assistance to deliver vaccines, therapeutics, and diagnostics for SARS-CoV-2 to the American public as quickly as possible.

Read More

14 September 2020 NIH Launches Clinical Trials of Antithrombotic for COVID-19

Two of three planned adaptive phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19 have launched, according to an announcement by the National Institutes of Health (NIH).

Read More

14 September 2020 NIH ACTIV Initiative Launches Adaptive Clinical Trails of Blood-Clotting Treatments for COVID-19

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Read More

14 September 2020 ACTIV-4 Antithrombotics Launched to Investigate Blood Thinners to Treat COVID-19 Patients

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Read More

13 September 2020 NIH ACTIV Initiative Begins Adaptive Clinical Trials of Blood Clotting Treatments for COVID-19

Learn more about NIH’s ACTIV-4 clinical trials aimed at reducing blood clotting in patients with COVID-19 with NIH Director Dr. Francis Collins and NIH’s National Heart, Lung, and Blood Institute Director Dr. Gary Gibbons.

Read More

10 September 2020 NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Read More

10 September 2020 Learner Team Plays Role in NIH COVID-19 Blood Clotting Treatment Trials

The University of Vermont (UVM) is participating in a major national research effort to evaluate the safety and effectiveness of varying types of blood thinners to treat adults diagnosed and hospitalized with COVID-19—the disease caused by SARS-CoV-2. The National Institutes of Health (NIH) announced the launch of two of three adaptive Phase 3 clinical trials September 10.

Read More

08 September 2020 NIH clinical trial explores use of convalescent plasma in at-risk outpatients with early COVID-19

Researchers supported by the National Institutes of Health have launched a key study to explore the safety and effectiveness of convalescent plasma in treating patients who have recently (within the last week) developed mild to moderate symptoms of COVID-19 disease. The study, which focuses on patients not yet hospitalized, comes on the heels of an announcement by the U.S. Food & Drug Administration (FDA) authorizing emergency use of convalescent plasma to help treat hospitalized patients with COVID-19.

Read More

01 September 2020 Event: Launching CONNECTS: Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies

Topic: Launching CONNECTS (Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies): A Partnership Between Research Triangle Institute, Vanderbilt University Medical Center, and the NHLBI. Date: Friday, September 11, 2020, 1:00-2:00 p.m. ET

Read More

13 August 2020 RTI researchers to help coordinate federal program seeking COVID-19 treatments

Federal health officials have tapped RTI International to join a collaboration tracking COVID-19’s ability to cause severe illness and the effectiveness of proposed treatments.

Read More

10 August 2020 Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

Read More

03 August 2020 4 former FDA commissioners: Blood plasma might be the covid-19 treatment we need

Blood plasma — also known as convalescent plasma — has been used as a therapy for infectious diseases for a century, including against the flu in 1918 as well as SARS, Ebola, meningitis and measles. While it doesn’t work for all infections, the idea is to use one person’s successful defense system of antibodies to bolster the immune response of a newly infected person.

Read More

30 July 2020 C3PO Clinical Trial

Michigan Medicine and three other medical centers receive $7 million for COVID-19 outpatient convalescent plasma therapy trial.

Read More

29 July 2020 COVID-19 trial to study convalescent plasma in outpatient setting

The Data Coordination Unit (DCU) in the Department of Public Health Sciences at the Medical University of South Carolina will take on the role of Data Coordinating Center for a $7 million national trial studying the role of convalescent plasma in mitigating the symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

Read More

28 July 2020 Pitt Collaborative to Study Outpatient Convalescent Plasma

A team of University of Pittsburgh, Michigan Medicine, Medical University of South Carolina and Stanford Medicine researchers recently were awarded funds from the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), totaling more than $7 million to collaboratively study the role of convalescent plasma in mitigating symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

Read More

27 July 2020 Phase 3 clinical trial of investigational vaccine for COVID-19 begins

A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun.

Read More

24 July 2020 COVID-19 Therapeutics Prioritized for Testing in Clinical Trials

The ACTIV public-private partnership has evaluated and prioritized therapeutic agents with potential application for COVID-19; and selected numerous NIH-supported networks to launch clinical trials to test prioritized therapeutic candidates.

Read More

20 July 2020 CHOC Hematologist Appointed to National COVID-19 Therapy Evaluation Oversight Committee

Dr. Diane Nugent has been named co-chair of the Steering Committee for the National Heart, Lung, and Blood Institute (NHLBI) Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies, or CONNECTS, which will coalesce projects into a national, coordinated effort. She will also serve on the Executive committee for CONNECTS to facilitate the rapid turnaround and implementation of these grants throughout the country.

Read More

15 July 2020 Launch Announcement: Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS)

The NHLBI’s Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) is an important and innovative research effort. The goal of CONNECTS is to build on NHLBI’s existing clinical research networks across the nation and around the world to better understand the risk of severe illness from COVID-19 and to identify therapies that will slow or halt the disease progression and speed recovery.

Read More

13 July 2020 NHLBI's COVID-19 Research Strategy

Given the major impact of underlying heart, lung, and blood diseases and conditions on morbidity and mortality among patients with Coronavirus Disease 2019 (COVID-19), the NHLBI is pursuing a multi-pronged research strategy that leverages NHLBI-supported expertise, research, and infrastructure.

Read More